ContributorsPublishersAdvertisers

MD Anderson and Eisbach Bio Announce Strategic Collaboration to Develop Medicines Targeting Epigenetic Machinery in Oncology

onclive.com
 2022-01-24

The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution. The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today...

www.onclive.com

Comments / 0

Comments / 0